Tema Etfs LLC Purchases 25,997 Shares of Bristol Myers Squibb Company $BMY

Tema Etfs LLC boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 34.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 102,238 shares of the biopharmaceutical company’s stock after purchasing an additional 25,997 shares during the quarter. Tema Etfs LLC’s holdings in Bristol Myers Squibb were worth $4,611,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Norges Bank purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at about $1,554,154,000. Charles Schwab Investment Management Inc. boosted its position in shares of Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after purchasing an additional 10,195,775 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Bristol Myers Squibb by 428.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after buying an additional 9,171,098 shares during the last quarter. Man Group plc increased its position in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Bristol Myers Squibb by 142.8% in the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock worth $390,541,000 after acquiring an additional 4,961,869 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 0.0%

Shares of Bristol Myers Squibb stock opened at $55.92 on Monday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The company’s 50 day moving average is $50.93 and its 200 day moving average is $47.81. The company has a market cap of $113.84 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 9.25 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be issued a $0.63 dividend. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date of this dividend is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wells Fargo & Company lifted their target price on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Citigroup reaffirmed a “neutral” rating and issued a $53.00 price objective (up from $45.00) on shares of Bristol Myers Squibb in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $56.62.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY, citing improved fundamentals and/or valuation support from recent earnings and guidance — a boost for investor confidence and likely a contributor to buying interest. Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by UBS Group
• Positive Sentiment: Piper Sandler reiterated a buy rating for BMY, reinforcing sell‑side support and reducing downside risk from analyst sentiment. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: BioNTech and Bristol Myers Squibb expanded a pancreatic cancer program with a new Phase II trial — clinical progress in a high‑need oncology indication improves long‑term upside potential if data are positive. BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial
• Positive Sentiment: BMY added a new immunotherapy combo in small‑cell lung cancer, broadening its oncology pipeline and potential label-expansion or combination opportunities. Pipeline depth tends to support premium multiples in pharma names. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Neutral Sentiment: Analyst/industry pieces (Argus, Yahoo valuation reviews, and a Zacks recap) note BMY’s recent share gains and evolving profitability story but raise valuation questions as shares have recovered — these provide context but no immediate directional trigger. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: CNBC preview of the JPMorgan Healthcare Conference highlights that the event could be a catalyst (pipeline updates, commercialization and M&A talk) for BMY, but outcomes depend on what management and peers announce. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Headline pieces summarizing recent developments (Yahoo/TipRanks recaps) provide useful investor reading but are largely descriptive rather than delivering a single market-moving event. How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.